Disclaimer

The website is targeted at investors qualifying as professional investors under MiFID (Directive 2004/39/EU) only. Retail investors are therefore kindly asked to leave this website.

The website and its content is not intended for US Persons, who are kindly asked to leave the website and visit CWorldWide.com/US/

By continuing to use the website, you confirm that you are a non-US person qualifying as a professional investor.

Choose your local website by clicking the globe in the right corner.

The content of the website is for information purposes only. The information does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any of the products or services mentioned on the website. The information, calculations, etc. on the website shall not be considered investment advice or requests to engage in investment operations.

All reasonable precautions have been taken to ensure the correctness and accuracy of the information available through the website. However, the correctness and accuracy is not guaranteed and C WorldWide Asset Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions. Neither is C WorldWide Asset Management Fondsmaeglerselskab A/S responsible for the suitability of the information on or the content of the website. The information on the website may be amended by C WorldWide Asset Management Fondsmaeglerselskab A/S at any time without notice.

The website and its content has been prepared in accordance with Danish law and the information provided may not satisfy the laws of any other country.

Past performance is not a reliable indicator of future performance.

Leave
Accept
ⓒ C WORLDWIDE ASSET MANAGEMENT FONDSMAEGLERSELSKAB A/S | DAMPFAERGEVEJ 26 | DK-2100 COPENHAGEN | CVR: 78 42 05 10

C WORLDWIDE BIOTECHNOLOGY (1A) AS OF 30 NOVEMBER 2017

NET OF FEES IN EUR

STRATEGY

The investment objective of the C WorldWide Biotechnology fund is to achieve long-term capital growth by investing globally in a limited number of biotechnology companies. Investments are made in small and medium-sized fast-growing and research-intensive companies.

Our management team has a close collaboration with a scientific advisory board made up of leading scientists at the Karolinska Institute. This gives us unique insight into the forefront of medical research and valuable knowledge for example in evaluating the commercial potential of research projects.

Our investment decisions are based on thorough, fundamental equity research. This analysis is combined with dialogue with scientists as mentioned above and creates opportunities to put together a concentrated portfolio of 25-50 companies which we have detailed knowledge of, and which in our opinion constitute the most interesting investment opportunities in the long term.

 

INVESTMENT RETURNS

C49D32 Portfolio 676766 Benchmark

TOP 10 HOLDINGS

Share in %
Gilead Sciences 7.8 %
Biogen 7.5 %
Celgene 7.3 %
Vertex Pharmaceuticals 7.3 %
Incyte 4.5 %
Biomarin Pharma 3.8 %
Alexion Pharmaceuticals 3.6 %
Bluebird Bio 2.9 %
Insmed 2.8 %
Sarepta Therapeutics 2.8 %

RETURN & RISK

1 Y 3 Y 5 Y 10 Y Lifetime P.A.
Portfolio (%) 2.6 -2.2 105.2 230.8 184.8 6.3
Benchmark (%) 2.7 9.6 151.9 376.5 88.6 3.8
Relative performance (%) -0.1 -11.8 -46.7 -145.7 96.2 2.5
3 Y 5 Y 10 Y Lifetime P.A.
Std. dev. portfolio (%) 32.0 28.6 23.9 26.1 26.1
Std. dev. benchmark (%) 26.1 25.2 22.0 25.7 25.7
Beta 1.2 1.1 1.0 0.9 0.9

GEOGRAPHIC DIVERSIFICATION

SECTOR EXPOSURE

FACTS

Security identifier (ISIN): LU0119485372
Launch date: 8 November 2000
Management fee: 1.10% per annum
Dealing frequency: Daily
Base currency: EUR
Minimum investment: EUR 1,000
Benchmark: NASDAQ Biotechnology Index®
NAV at month end: 28.48
Fund AUM: 10.9 million
Investment Manager: C WorldWide Asset Management, Stockholm
Portfolio Manager: Ulf Arvidsson

DISCLAIMER

The fact sheet is for information purposes only. The fact sheet does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any fund. The information, calculations etc. shall not be considered investment advice or requests to engage in investment operations.

All reasonable precautions have been taken to ensure the correctness and accuracy of the fact sheet. However, the correctness and accuracy is not guaranteed and C WorldWide Asset Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions.

It is emphasized that the figures in the fact sheet are historical, and that past performance is no reliable indicator of future performance.